Incremento de supervivencia en melanoma - page 7

RR 27

10%

Nivolumab post-Ipi en melanoma:

Primary objectives

Weber et al. Lancet Oncology 2015; SMR 2016

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1,2,3,4,5,6 8,9,10,11,12,13,14,15,16,17,...29